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Abstract
Background: To study the effect of Interferon (INF) alpha-2b therapy on the serum lipids and fatty acid (FA) level in
pre and post treated hepatitis C (HCV) patients.
Methods: Fifty samples were collected from pre and post treated patients along with age and gender matched
controls. After separating serum, lipid contents were analyzed by microlab and gas chromatography.
Results: The hepatitis C infection results in hypolipidemia with reduced level of triglyceride (113 mg/dl), high density
lipoprotein (37.1 mg/dl), low density lipoprotein (74.3 mg/dl), cholesterol (149.9 mg/dl) that increase the infection
resolution and after the IFN treatment, the lipid profile of the patients were increased. The myristic (2.8 g/100 g) and
palmitic acids (26.6 g/100 g) were significantly higher while linoleic acid (20.94 g/100 g) was significantly lower in HCV
patients. The higher oleic: stearic (1.4) and palmitoleic: palmitic acid (0.2) ratios were detected in HCV patients, showing
enhanced stearoyl-CoA desaturase activity. The levels of serum saturated (44.9 g/100 g) and monounsaturated FA’s
(26.98 g/100 g) were higher while polyunsaturated FA’s (25.9 g/100 g) were found lower in HCV patients in comparison
of controls (40.1; 25.01; 33.44 g/100 g respectively). An inverse correlation was found HCV RNA viral load and
PUFA (R2 = 0.4555). Elevated levels of serum saturated free FA (45.7 g/100 g) in HCV patients indicates
stimulated lipoapoptosis.
Conclusion: The present study conclude that serum PUFA level was lower in HCV patients, hence PUFA may
provide synergistic antiviral effects when given as a food supplement during the INF based anti- HCV therapy.
Keywords: Hepatitis C virus, Alpha-2b interferon, Fatty acids, Cholesterol, GC-FID, Triacylglycerol, High density
lipoprotein, Low density lipoprotein, Saturated fatty acid, Polyunsaturated fatty acid
Introduction
The viruses of family flaviviridae cause the most widely
spreading diseases across the world [1]. Among those
diseases hepatitis C virus (HCV) is predominant one
which belongs to genus Hepacivirus [2]. Worldwide,
liver cancer is the second leading cause of cancer related
death in men and the sixth in women. Due to hepatitis
B virus (HBV) or HCV approximately 78 % of hepatocel-
lular carcinoma (HCC) appears in patients which in turn
accounts for 80 % of liver cancer cases [3].
In Pakistan, hepatitis B and C infection rate is increasing
gradually due to unavailability of appropriate health facil-
ities or poor socio-economical status and less public
awareness about the transmission of hepatitis B, C and
human Immunodeficiency Virus [4]. Patients suffering
with hepatitis C virus leads to 29 % of patients with
chronic liver disease and 8 % of patients with hepatocellu-
lar carcinoma in Pakistan [5, 6].
The liver plays a central role in lipid metabolism, and
major metabolic processes take place at this level, involv-
ing the production, transportation and storage of lipopro-
teins, as well as catabolism of various lipids including
excretion of cholesterol and phospholipids. An alteration
in liver functions resulting from cellular injury leads to
changes in the serum concentration of cholesterol and
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lipoproteins. An HCV virus leads to hepatic damage,
which in turn relates to changes in alterations of the lipid
metabolism [7].
Both fatty acids (FA) and cholesterol are playing major
role in progression of HCV. Lipid storage in liver is lead-
ing to steatosis, which is caused by de novo lipogenesis,
may contribute to HCV-induced damage by involvement
of viral replication process. Sterol regulatory-element
binding protein 1c and FA synthase enzyme is involved in
lipogenic pathway and HCV is proposed to stimulate hep-
atic FA synthesis by up-regulation of these enzymes [8].
Progress seems to be happening rapidly in the Hepa-
titis C drug treatment arena. Approved by the U.S. Food
and Drug Administration (FDA) in 2011, Incivek was ap-
parently astounding new Hepatitis C drug. While it
greatly improved the likelihood of beating the Hepatitis
C virus in 2011, Incivek has already been discontinued
effective October 2014. At the end of 2014 of effective
interferon-free, hepatitis C treatments with Gilead’s
Sovaldi, Gilead’s Harvoni and AbbVie’s Veikira Pak has
been introduced. Although they may or may not also re-
quire the addition of ribavirin during the course of ther-
apy, these effective, all oral medications come with a
high price tag. However, interferon alfa-2b is FDA ap-
proved to treat chronic hepatitis C as well as hairy cell
leukemia, malignant melanoma, condylomata acuminate
and AIDS-related Kaposi’s sarcoma [9].
The standard interferon alpha -2b and interferon plus
ribavirin therapies is to be considered the first line treat-
ment for chronic hepatitis C patients. These therapies
have been used in Pakistan since 1998 till now [10].
Although Interferon (IFN) is the one of the proven ef-
ficacy in the treatment of hepatitis C, though its mecha-
nisms of treatment failure are inadequately understood,
earlier reports have proposed IFN-stimulated genes and
the inability to develop effective anti-HCV immunity as
possible explanations [11]. In liver diseases, especially in
non-alcoholic steatohepatitis, the effect of impaired per-
oxisomal polyunsaturated fatty acid (PUFA) metabolism
and non-enzymatic oxidation on FA constitution is asso-
ciated with disease progression [12]. It has been reported
that HCV core protein has effects on FA synthesis, and
that fatty droplets in the liver are related to development
of disease. However the relationship between serum FA
and efficacy of IFN-based antiviral therapy against HCV
remains controversial [13].
Thus the aim of current study is to determine the vari-
ations in serum lipid and FA due to interferon alpha-2b
treatment in pre and post treated acute HCV patients in
comparison of healthy controls.
Material and methods
Acute HCV infection is defined as the inflammation
resolves within 6 months. Acute HCV patients were
diagnosed by center of diseases control (CDC) cri-
teria; the patients do not have symptomatic non-
specific symptoms that may include malaise, anorexia,
and abdominal pain [14]. The patients came in Taluka
hospital TandoAdam with these symptoms, their blood
samples were subjected to ELISA and ALT test. Elevated
ALT levels were found in HCV positive patients
(Table 1). The results were further confirmed by PCR
HCV RNA active replication (>10–50 reactive and <10
non-reactive). All patients signed a written consent and
were enrolled in the study. The study was approved by
ethnic committee Institute of Biochemistry University
of Sindh, Jamshoro.
The male and female patients (age 18–56 years) with
acute hepatitis C (n =100) were enrolled before starting
the antiviral therapy during February 2012 to December
2013 treated in Taluka hospital TandoAdam, district
Sangher, Sindh Pakistan. The patients were treated by
Ceron alpha (interferon alpha 2b, injection 3MIU). Dia-
betic, hypertensive and having hepatitis co-infection,
those taking supplementation of antioxidants, vitamins
and PUFA, having pregnancy or lactating patients were
excluded from present study. Age and sex matched con-
trols (n = 50) having normal ALT levels and negative
HCV RNA (ELISA) were selected for comparison.
Five ml intravenous blood samples from pre and post
treated (after 1 week of treatment) patients and controls
were collected after 14 h over night fasting. Serum was
separated and stored at – 40 °C until analyzed for lipid
profile and fatty acids by microlab 300 and gas chro-
matograph 8700 (Perkin–Elmer Ltd). Lipid profile in-
clude total cholesterol (TC), triacylglycerols (TAG), total
lipid (TL), low density lipoprotein - cholesterol (LDL-C),
high density lipoprotein - cholesterol (HDL-C), by kit
method (Merck, Germany) based on microlab measure-
ments [15]. FA composition was analyzed by gas chro-
matography (GC). All solvents and reagents used during
the study were of analytical grade.
FAs were analyzed as total fatty acid (TFA) and free
fatty acid (FFA). The samples for TFA and FFA were
prepared as per reported method [16].
2FA analysis was performed on a model 8700 Perkin–
Elmer Ltd., (Buckinghamshire, England) fitted with non-
bonded biscynopropylsiloxane stationary-phase, polar
capillary column Rt-2560 (100 m × 0.25 mm) 0.2 μm film
Table 1 Demographic characteristics of HCV patients and
controls
Demographic characteristics Controls Patients
Mean age (years) 34.2 ± 3.8 34.1 ± 4.2
Mean body weight (Kg) 58.0 ± 8.2 56.6 ± 7.5
Body mass index (BMI) 22.4 ± 1.2 23.1 ± 1.5
ALT levels (IU) 26.5 ± 14.1 77.6 ± 33.4
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thickness (Supelco, PA, USA) and Flame ionization de-
tector. Oxygen-free nitrogen was used as a carrier gas at
a flow rate of 3.5 mL/min. The initial oven temperature
was 120 °C at rate of 4 min which was raised to 220 °C
held for 20 min. The injector and detector temperature
were set at 260 °C and 270 °C, respectively. A sample
volume of 2.0 μl was injected.
Peaks were identified by authentic standards supplied
by Fluka Chemika (Buchs, Switzerland). The FA stan-
dards, includes myristic acid (C14:0), myristoleic acid
(C14:1), palmitic acid (C16:0), palmitoleic acid (C16:1w9),
α-linolenic acid (C18:3w3), stearic acid (C18:0), linoleic
acid (C18:2w6), oleic acid, vaccenic acid (C18:1), eicosa-
pentaenoic acid (EPA (C20:5w3), arachidonic acid
(C20:4w6) arachidic acid (C20:0), docosahexaenoic acid
(DHA (C22:6w3), docosenoic acid (C22:1), nervonic
acid(C24:1) and eicosatrienoic acid (C-20:3). The FA com-
position was reported as a relative percentage of the total
peak area.
Statistical analysis
The values are expressed as mean ± SD. For the associ-
ation among the groups ANOVA was used with SPSS
version 15 (SPSS Inc. Chicago, IL). P value is <0.05
considered statistically significant. Conditional logistic-
regression analysis was performed using the SAS statis-
tical software (version 9.1; SAS Institute, Inc., Cary,
North Carolina). Odds ratios and 95 % confidence inter-
vals (CI) were calculated to estimate the risk factor for
quartiles as well as for continuous variables. Tests for
trend were performed by using the means within each
category in the logistic-regression model. Quartile cut
points were determined by distribution of the fatty-acid
levels among the referents, and the lowest quartile was
used as the reference category.
Results
Most commonly, acute hepatitis C infection is defined
as the 6-month time period following acquisition of
hepatitis C virus. The definition of acute hepatitis C is
irrespective to whether the patient has clinical signs or
symptoms of acute hepatitis. The rationale for choosing
6 months as the time period to define acute infection is
based on evidence that most individuals who clear
HCV will do so by 6 months. The CDC establish a gold
standard for the laboratory diagnosis of acute HCV is
anti- HCV seroconversion (negative anti-HCV before
suspected exposure and positive anti-HCV following
potential exposure), combined with a positive HCV
RNA test and elevated ALT.
One hundred acute HCV patients consented and 30
patients were disqualified suffering from diabetes, malnu-
trition, hypertension, hyperthyroidism, renal failure, ma-
lignancy and immunoglobulin disorders. 20 patients
were dropped out from the study, as they did not
complete the 6 month treatment. Therefore only 50
patients completed the treatment and included in the
present study. The median age of all patients was
34.1 years, BMI 23.1 and 50 % were female (Table 1).
All patients were responders and completed the
6 month treatment and HCV RNA becomes non-
reactive.
We found serum total lipids, total cholesterol, HDL-C,
LDL-C, TAG in HCV pretreated patients were decreased
as compared to controls. Whereas, after the interferon
therapy lipid contents were increased and got back to
normal ranges. The significant difference was observed
in HDL-C and LDL-C and high HDL/LDL ratio shows
coronary risk among the HCV patients as compared to
controls (Table 2).
The result of total FA composition of pre and post
treated acute HCV patients with contrast of healthy con-
trols reveals that myristic and palmitic acids were signifi-
cantly higher while linoleic acid was significantly lower
in acute HCV patients. Stearic and docosenoic acids
were elevated in pretreated patients and reduced after
therapy. The palmitoleic acid was increased in both pre
and post patients. The myristoleic, oleic, α-linolenic, ara-
chidonic and arachidic acid were increased after INF
treatment. The nervonic acid and DHA were not de-
tected in both categories while in post treated acute
HCV patients eicosatrienoic acid was not determined in
comparison to healthy subjects. The oleic: stearic and
palmitoleic: palmitic acid ratios, which are considered as
a marker for stearoyl-CoA desaturase (SCD = Δ9-desa-
turase) activity was found higher in acute HCV patients,
While PUFA: SFA was lower in acute HCV patients as
compared with control subjects (Table 3).
The serum free FA profile of acute HCV patient’s,
shows significantly higher palmitic and stearic acid in
pre-treated patients, which was reduced after therapy.
The myristoleic, linoleic, arachidonic and EPA were
Table 2 Comparison of lipid profile of Control subjects with pre
and post treated HCV patients





Cholesterol mg/dl 170.1 ± 9.7 149.9 ± 49.0 169.5 ± 18.8
LDL mg/dl 102.8 ± 5.2a 74.3 ± 35.9b 97.5 ± 2.9c
HDL mg/dl 55.5 ± 7.8a 37.1 ± 11.2b 45.7 ± 8.9c
Triglyceride mg/dl 126.5 ± 12.1 113.1 ± 54.1 123 ± 19.7
Total lipid mg/dl 543.8 ± 34.2 491.7 ± 161.0 533.2 ± 43.9
Coronary risk
(HDL/LDL Ratio)
0.5 ± 0.07 0.6 ± 0.3 0.5 ± 0.1
Values represent mean ± Standard deviation of triplicates. Different alphabets
on the same row indicate significant difference at p <0.05
LDL Low density lipoprotein, HDL High density lipoprotein, TAG Triglyceride
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significantly lower in acute HCV patients and increased
after INF treatment. The EPA was not detected in post
patients. The myristic, arachidic, palmitoleic acid were
elevated in both pre and post-acute HCV patients. The
oleic, α-linolenic, eicosatrienoic acid were reduced in
acute HCV patients and the level of these FAs was en-
hanced after the treatment (Table 4).
The total SFA and MUFA were higher while PUFA
(n – 3 and n – 6) contents were lower in acute HCV
pre-treated patients in comparison of controls. After
the INF therapy the PUFA concentration was im-
proved in patients (Fig. 1) but was found lower than
controls.
Figure 2, elucidates the free FA composition in acute
HCV pre and post patients in contrast of controls. The
saturated FFA was elevated, whereas the free MUFA and
PUFA were lower in acute HCV patients in association
of controls. After the INF therapy both MUFA, and
PUFA were augmented and amount of SFA was abridged
in acute HCV patients.
The inverse correlations was found between viral
load and PUFA levels with R2 0.4555 as depicted in
Fig. 3. Odds ratios were calculated (Table 5) for hepa-
titis C pretreated patients and controls by quartile of
serum fatty acids. The significant association between
serum fatty acids and hepatitis C virus was found
when we compared the myristic acid odds ratio for
Table 3 Total Fatty acid profile of HCV patients (pre and post)
in comparison of controls




C – 14:0 1.1 ±
3.2a
2.8 ± 1.7b 1.9 ± 0.7c
C - 16 : 0 23.9 ±
5.3a
26.6 ± 3.8b 27.8 ± 2.3c
C - 18 : 0 14.7 ±
5.4
15.4 ± 5.12 12.3 ± 3.1
C - 20 : 0 0.4 ± 1.1 0.3 ± 0.9 0.4 ± 0.8
C - 14 : 1 0.5 ± 0.9 0.3 ± 2.2 0.4 ± 0.4
C - 16 : 1 2.6 ± 2.2 3.2 ± 1.4 3.8 ± 1.1
C - 18 : 1 19.8 ±
4.6
19.6 ± 3.6 20.9 ± 1.8
C - 22 : 1 1.9 ± 1.4 2.7 ± 1.4 2.3 ± 0.8
C – 24 : 1 0.3 ± 0.7 ND ND
C - 18 : 2 25.0 ±
5.4a
20.9 ± 5.8b 21.6 ± 4.1c
C - 18 : 3 0.8 ± 1.3 0.3 ± 1.0 0.7 ± 0.9
C - 20 : 4 5.9 ± 2.1 5.1 ± 1.6 5.3 ± 0.8
C - 20 : 5 0.9 ± 1.7 0.6 ± 1.3 0.5 ± 0.9
C - 20 : 3 0.4 ± 0.6 0.2 ± 0.9 ND









PUFA: SFA 1.0 0.6 0.8
Values represent mean ± Standard deviation of triplicates. Different alphabets
on the same row indicate significant difference at p <0.05. myristic acid
(C14:0), myristoleic acid (C14:1), palmitic acid (C16:0), palmitoleic acid (C16:1),
stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2), α-linolenic acid
(C18:3), arachidic acid (C20:0), eicosatrienoic acid (C-20:3), arachidonic acid
(C20:4), eicosapentaenoic acid (EPA (C20:5), docosenoic acid (C22:1),
docosahexaenoic acid (DHA (C22:6), nervonic acid(C24:1), not detected (ND)
Table 4 Free fatty acid composition of HCV patients (pre and







C – 14:0 1.5 ± 0.6 2.0 ± 1.1 2.0 ± 0.5
C - 16 : 0 23.8 ± 3.6a 28.6 ± 5.9b 25.8 ± 2.5c
C - 18 : 0 10.8 ± 4.1a 14.4 ± 5.4b 10.2 ± 1.7a
C - 20 : 0 0.5 ± 0.9 0.6 ± 2.1 1.6 ± 1.1
C - 14 : 1 0.1 ± 0.3a NDb 0.2 ± 0.4c
C - 16 : 1 2.8 ± 1.4 3.5 ± 1.5 3.8 ± 1.2
C - 18 : 1 20.7 ± 2.9 19.9 ± 3.9 21.6 ± 2.1
C - 22 : 1 2.2 ± 1.3 2.2 ± 1.3 2.8 ± 1.0
C - 18 : 2 29.9 ± 4.6a 21.2 ± 4.6b 23.8 ± 5.6c
C - 18 : 3 0.4 ± 1.1 0.2 ± 0.6 0.4 ± 0.7
C - 20 : 4 6.1 ± 1.6a 4.4 ± 1.4b 5.3 ± 0.9c
C - 20 : 5 1.0 ± 1.6a 0.4 ± 0.9b NDc
C - 20 : 3 0.2 ± 0.7 0.1 ± 0.5 0.5 ± 1.3
Values represent mean ± Standard deviation of triplicates. Different alphabets
on the same row indicate significant difference at p < 0.05
Myristic acid (C14:0), myristoleic acid (C14:1), palmitic acid (C16:0),
palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1), linoleic acid
(C18:2),
α-linolenic acid (C18:3), arachidic acid (C20:0), eicosatrienoic acid (C-20:3),
arachidonic acid (C20:4), eicosapentaenoic acid (EPA (C20:5), docosenoic
acid (C22:1), docosahexaenoic acid (DHA (C22:6), nervonic acid(C24:1), not
detected (ND)
Fig. 1 Comparison of SFA, MUFA, PUFA including n-3 and n-6 fatty
acids in total FA composition of Controls and HCV patients (pre
and post)
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the highest quartile with the lowest one 2.0 (95 % CI:
0.08, 97.8; p for trend = 0.0003), palmitic acid odds ra-
tio was 2.6 (95 % CI: 0.4, 20.6; p for trend = 0.0002)
and docosenoic acids odds ratio was 2.7 (95 % CI:
0.6, 12.2; p for trend = 0.001). Present study found an
increased risk of hepatitis C virus replication associ-
ated positively with increasing levels of myristic, pal-
mitic and docosenoic acids. On the contrary PUFA
was inversely correlated with hepatitis C virus replica-
tion with odds ratio ≤0.9.
Discussion
We have reported the importance of lipid factors on IFN
alpha – 2b therapy by evaluating lipid profile and FA com-
position of acute HCV patients before and after treatment.
The low lipid profile was identified as contributing factor
in acute HCV patients before treatment. Further analysis
was performed to examine the relationship of FA levels to
the response of IFN therapy. The IFN might alter the me-
tabolism of lipids through receptors on hepatocytes, enter-
ocytes and adipocytes which play major role in the serum
Fig. 2 Comparison of Free SFA, MUFA, PUFA including n-3 and n-6 fatty acids in free FA composition of Controls and HCV patients (pre
and post)
Fig. 3 Correlation between HCV RNA viral load and PUFA among pre-treated HCV patients
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lipids regulation. The most important fact is HCV replica-
tion was suppressed and hepatocytes may normalize their
function because HCV has direct affect on hepatocyte
lipid metabolic functions [17].
The present study suggests that elevated serum level
of SFA and MUFA, while low level of PUFA could be a
predictive factor for virological response to IFN-based
therapy in acute HCV patients. The changes were
reverted to base line after the treatment, significant in-
crease in lipid profile was observed. The significance
and mechanism of these changes is not clear, but it has
been reported that HCV may alter expression profile of
lipid metabolism–associated with genes [18]. Sterol
regulatory element-binding proteins (SREBPs) are genes
encoding enzymes involved in cholesterol and fatty acid
biosynthesis, whereas SREBP-2 plays an important role
in cholesterol biosynthesis, SREBP-1c is involved in
fatty acid biosynthesis, which regulates the expression
of its enzymes in the liver, e.g., fatty-acid synthase
(FAS) and SCD [19].
The observed changes in FA composition in acute
HCV patients indicate dysregulations of enzymatic con-
version steps. The higher relative amount of MUFA and
higher oleic: stearic and palmitoleic: palmitic acid ratios
in HCV patients propose increased activity of SCD. It is
rate-limiting enzyme involved in the synthesis of MUFA
from SFA. As reported earlier that hepatic steatosis is
developed by involvement of SDC, authors have shown
that SCD1-deficient mice were resistant to diet-induced
obesity and steatosis. The decreased lipogenesis and en-
hanced β-oxidation leading to the underlying mecha-
nisms might involve regulation of transcription factors,
like the SREBP-1 [20].
It has been well-known that infection with HCV virus
leads to hepatic damage, which in turn relates to changes
in alterations of the lipid metabolism. As evident from
present study a consistent strong association exists be-
tween acute HCV infection and low levels of total choles-
terol, TAG, LDL and HDL that increase the infection
resolution. Corey et al., [21] reported that chronic hepa-
titis C patients have lower cholesterol and LDL levels. This
association persists when controlled for sex, race, and
BMI, further strengthen this association by examining the
change in lipid levels when hepatitis C is eradicated com-
pared to patients who do not respond to treatment. Differ-
ent mechanisms are involved, dependent on the stage of
the liver disease and the metabolic state [22]. Moreover,
there may be clinical implications for HCV-associated
dyslipidemia [23]. Nutraceutical foods provide medical or
health benefits for the prevention and treatment of dis-
eases. The role of nutraceuticals and functional foods in
dyslipidemia has been reported to act by reducing 7α-
hydroxylase, increasing faecal excretion of cholesterol, de-
creasing 3-hydroxy-3-methylglutarylCoA reductase mRNA
levels or reducing the secretion of very low density
lipoprotein [24].
HCV infection can exert proatherogenic activities due
to its direct action on vessel walls and/or via the chronic
inflammatory process involving the liver [25]. The in-
flammatory condition related to liver infection could
negatively influence the vascular wall performance and
the cardiovascular system [26].
Several studies have shown that HCV core protein dis-
rupts FA homeostasis. HCV core protein has been
shown to significantly increase the proportion of oleic
acid, but not palmitic acid, in the livers of patients with
Table 5 Odd ratios for Hepatitis C patients and controls according to quintile of serum fatty acids
Fatty
acids
Odds ratio (95 % confidence interval)
1st Quartile 2nd Quartile 3rd Quartile 4th Quartile 5th Quartile P
valueReference
C – 14:0 1.00 1.8(0.4 – 9.3) 2.3(0.6 – 9.4) 2.6(0.5 – 13.4) 2.0 (0.04– 97.8) 0.0003
C - 16 : 0 1.00 1.8(0.3 – 13.5) 1.9(0.3 – 12.9) 3.4(0.6 – 20.3) 2.6(0.4 – 20.6) 0.0002
C - 18 : 0 1.00 0.3(0.06 – 1.7) 0.5(0.1 – 2.1) 0.8(0.2 – 3.3) 1.6(0.2 – 11.9) 0.21
C - 20 : 0 1.00 0.5(0.05 – 3.2) 0.9(0.02 – 35.3) 0.3(0.01 – 3.6) 1.9(0.1 – 53.4) 0.22
C - 14 : 1 1.00 0.8(0.02 – 35.8) 0.4(0.01 – 7.6) 0.4(0.01 – 7.6) 0.8(0.02 – 35.8) 0.27
C - 16 : 1 1.00 1.4(0.2 – 8.5) 2.1(0.4 – 11.1) 2.5(0.5 – 14.8) 1.4(0.2 – 8.7) 0.12
C - 18 : 1 1.00 2.7(0.4 – 18.8) 2.8(0.5 – 17.2) 1.1(0.2 – 7.9) 2.0(0.2 – 17.6) 0.411
C - 22 : 1 1.00 1.8(0.4 – 9.3) 2.5(0.6 – 11.1) 1.3(0.2 – 9.6) 2.7(0.6 – 12.2) 0.001
C - 18 : 2 1.00 0.5(0.08 – 2.3) 0.9(0.04 – 0.8) 0.2(0.04 – 0.9) 0.1(0.01 – 0.8) 0.002
C - 18 : 3 1.00 0.3(0.03 – 1.9) 0.1(0.004 - 0.8) 0.7(0.02 – 27.9) 0.4(0.01 – 5.5) 0.009
C - 20 : 4 1.00 0.8(0.1 - 4.6) 0.5(0.08 – 3.6) 0.5(0.08 – 3.3) 0.2(0.004 – 3.1) 0.008
C - 20 : 5 1.00 0.3(0.08 – 1.3) 0.2(0.008 – 1.9) 0.4(0.007 – 2.4) 0.7(0.07 – 8.0) 0.07
C - 20 : 3 1.00 0.1(0.005 – 1.0) 0.3(0.01 – 3.2) 0.8(0.02 – 31.2) 0.8(0.07 – 8.7) 0.17
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HCV infection. Irmisch et al. [27] compared FAs in
serum of female patients with untreated chronic HCV
infection with those treated with interferon-α and ribavi-
rin and healthy controls. They showed that women who
responded to treatment and healthy controls had signifi-
cantly higher levels of eicosapentaenoic and arachidonic
acid than did untreated HCV patients.
Present study found an increased risk of hepatitis C
virus replication associated positively with increasing
levels of myristic, palmitic and docosenoic acids. Previ-
ously, Kapadia et al., [19] and Leu et al., [28] have re-
ported enhanced HCV replication due to increase in
saturated FAs, including palmitic acid, whereas HCV
replication was suppressed by increasing polyunsatur-
ated FAs such as arachidonic acid in vitro.
Miyakes et al. [29] reported that the SFA may be re-
sponsible for impaired dendritic cells (DC) function. The
inflammation and impaired antigen-specific function of
DCs was due to palmitic acid in nonalcoholic fatty liver
disease (NAFLD) in humans and mice. An additional ex-
planation for the reduced effect of IFN-based therapy in
patients is related with palmitic acid potency to develop
ineffective anti-HCV immunity. These conditions are
similar as found in present study with acute HCV infec-
tion. The impaired function of DC in acute HCV infec-
tion is possibly due to the reduced anti-HCV immunity
by higher level of palmitic acid. Further studies are
needed to identify the mechanisms which are involved
in the effects of palmitic acid, including immunomodula-
tory effects.
In addition PUFA was found as protective factor for
HCV replication as evident from odds ratio calculated
for PUFA and viral load correlation. Huang et al. [30]
showed that arachidonic acid has an ability to inhibit
HCV replication by increasing lipid peroxidation, which
results in decreased HCV RNA level. The physiologically
relevant concentrations of arachidonic, DHA and EPA
exert anti-HCV (hepatitis C virus) activities. The anti-
HCV action of PUFAs is due to the formation of signifi-
cant amounts of lipid peroxides. As observed in present
study, an inverse correlation between HCV RNA and
PUFA levels was found indicating that viral load in-
creased with decrease in the PUFA concentrations.
PUFAs have long been known to suppress hepatic lipo-
genesis, reduce hepatic triglyceride levels, and induce
fatty-acid oxidation and degradation because previously
it is demonstrated that HCV RNA replication requires
fatty-acid synthesis [31]. The Sharookh et al., [32] re-
ported that PUFAs inhibit HCV RNA replication by a
mechanism that is independent of their ability to inhibit
lipogenic gene expression by antagonizing LXRα.
Moreover the chronic liver diseases had shown in-
creased oxidative stress, due to hepatocellular iron ac-
cumulation and the direct effect of the HCV core
protein. The reactive oxygen species including inflam-
matory cytokines such as tumor necrosis factor-α
(TNF-α) and interleukin-1β produced during the im-
mune response as activated phagocytes, which may
cause oxidative stress [33, 34]. In present study lower
EPA levels were observed in acute HCV pre and post
treated patients. EPA has a high susceptibility to oxida-
tion because it is a highly unsaturated fatty acid. The
oxidative damage is prevented during treatment by
antioxidant supplementation.
Arachidonic, DHA and EPA low levels were detected
in acute HCV pre and post treated patients. The biosyn-
thesis of various prostaglandins (PGs) and other eicosa-
noids are formed through FAs; as they are esterified in
position 2 of glycerol and upon activation of phospho-
lipases by physiologic or pathophysiologic stimuli; ara-
chidonic and EPA are released and oxidized by
cyclooxygenase and lipoxygenase. The synthesis of
PGE2 from ω 6 PUFAs is accelerated and especially
from arachidonic acid, which have an ability to sup-
press the production of type 1 cytokines [35]. The
concentration of saturated FFA was higher in acute
HCV pre and post treated patients. Malhi et al. [36]
reported that cellular steatosis is caused by FFAs;
which enhance expression of the apoptosis effectors
TNF-α. The cytotoxicty of saturated FFAs was found
higher than monounsaturated, therefore palmitic and
stearic acid exhibited greater cytotoxicity than oleic
and palmitoleic acid FFAs. The formation of reactive
oxygen species in the alternative lipid metabolic path-
ways, including ceramide synthesis, modulation of
death receptor expression and direct activation of cel-
lular proapoptotic machinery are putative mechanisms
involved in lipoapoptosis.
Conclusions
In acute HCV patients, before treatment elevated levels of
palmitic and myristic acid were found in serum, which
may enhance virus replication and inhibits the anti- HCV
effects of IFN therapy. The elevated levels of serum satu-
rated Free FA induces lipoapoptosis which may cause cel-
lular steatosis. PUFA play numerous important roles in
normal physiological conditions and progression of dis-
eases. The present study concludes that serum PUFA level
was lower in acute HCV patients including arachidonic,
α-linolenic and linoleic acids, which are reported to re-
duce HCV RNA level. Hence PUFA supplement can pro-
vide coadjuvant antiviral effects in the INF therapy.
Limitations of the study
In present study numbers of samples are not large
enough, though ideally larger group of subjects are re-
quired to delineate the role of lipid synthesis across the
HCV spectrum.
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